Answers are grounded in this paper and cite their sources.
The performance of plasma metagenomic next-generation sequencing was evaluated in an immunocompromised pediatric population. The clinical impact was limited, with management changes in 13% of cases. Moreover, organisms thought to be non-pathogenic were commonly detected. Prospective studies in specific populations are required to clarify the utility of this emerging technology.
No takes yet. Share an insight, caveat, or question.
Lehman et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: